A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
Nestlé Purina, a global leader in pet care, hosted its fourth annual Better with Pets Summit at the Brooklyn Expo Center in New York City on Tuesday, October 18, bringing together pet community experts and leaders across the nation to explore how pets and people are living bigger and better lives thanks to new research and innovation that will shape the future of pet care.
Featuring three interactive panel discussions, the Better with Pets Summit examined topics that continue to affect pet care and wellness including the evolving role of pets and their impact on people’s well-being, nutritional innovation that will allow pets to live healthier lives, and demystifying pet nutrition quality and safety standards.
To view the multimedia release go to:
http://www.multivu.com/players/English/7923051-purina-better-with-pets-2016-summit/
With the February launch of GOPO® Rosehip with Galactolipids, a natural, plant-based joint care supplement clinically proven to support joint health, the natural supplement is gaining traction and helping millions who suffer joint pain due to age, sports injuries, etc. Used extensively in Europe, GOPO is now available in the U.S. and proven effective in supporting long-term joint mobility and cartilage care.
GOPO Rosehip with Galactolipids is made from 100% specially-cultivated, natural rosehip using a patented extraction process and is the only product of its kind to contain a high level of galactolipids - a key component of the rosehip which may play a valuable role in the care of joints and joint tissues.
To view the multimedia release go to:
http://www.multivu.com/players/English/7918251-new-gopo-joint-care-all-natural-supplement/
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
After analyzing millions of Internet visits and interviewing scores of consumers, Brookdale Senior Living has built a new website based on fresh insights into what’s most important to families searching for senior care. The first phase, which is a $4 million investment, went live on brookdale.com mid-August.
“With Brookdale’s website attracting more than 500,000 visits every month, it’s imperative to make it as useful to consumers as possible,” said David Cygan, Brookdale’s senior vice president of marketing. “As the nation’s largest senior living provider, we know our website is a primary source of information, with many people coming to us first as they embark on this journey,” Cygan said. “It’s important that we offer substantive resources that make it easier to find help in evaluating senior care options.” More than 80 percent of adult children turn to the Internet when they look for care for an aging parent, according to the company’s research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7722159-new-brookdale-senior-living-website/
Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.
STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
Primrose Schools, a leading early education and child care franchise, is offering entrepreneurs the opportunity to pursue a meaningful and purposeful career by delivering a life-changing early learning experience for children and their families. The company is actively seeking Franchise Owners to independently own and operate schools across the country in response to national demand for high-quality early education and care providers.
According to USA Today, the majority of the American workforce would like to pursue a career with deeper, personal meaning; an overwhelming 82 percent of 40-59 year-olds surveyed said they want to give back more, and 75 percent said they want to make their lives more meaningful. Hundreds of entrepreneurs from a variety of professional backgrounds are fulfilling their dreams through ownership of a Primrose school. In fact, Primrose Franchise Owners are not required to have a background in education. The common denominator uniting each person who owns and operates a Primrose school is an entrepreneurial spirit and a passion for educating the next generation of leaders.
To view the multimedia release go to:
http://www.multivu.com/players/English/7727751-primrose-schools-franchise-owners/
Kiehl’s Since 1851, the New York-based purveyor of fine quality skin and hair care, continues its enduring support of HIV/AIDS charities with its seventh annual Kiehl’s LifeRide for amfAR, an 11-day charity motorcycle ride.
On August 3rd, LifeRide commenced with contemporary artist José Parlá, in partnership with RxArt, with an unveiling of original work by Parlá at Incarnation Children’s Center (ICC). ICC is New York City’s only skilled nursing facility providing specialized care for youth living with HIV/AIDS.
To view the multimedia release go to:
http://www.multivu.com/players/English/7896051-kiehls-liferide-amfar/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
With 830 women dying every day from preventable causes related to pregnancy and childbirth, and over 16,000 children under age five dying daily, Bayer and the White Ribbon Alliance today released critical policy recommendations and launched community programs to support the reduction and prevention of maternal, newborn and child mortality in two developing countries.1,2
Established through a three-year $1.3 million commitment from Bayer, these programs will expand work conducted by White Ribbon Alliance in Bangladesh and Zimbabwe to support the United Nations Secretary General’s Every Woman Every Child movement.
This announcement comes at the one-year anniversary of the Bayer/White Ribbon Alliance commitment in support of the Every Woman Every Child movement and will contribute to the success of the Sustainable Development Goals.
To view the multimedia release go to:
http://www.multivu.com/players/English/77126510-bayer-white-ribbon-alliance-self-care/
